Janus Henderson Investors US’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Janus Henderson Investors US’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$121M	Sell	1,454,778 -29,463	-2%	-$2.19M	0.1%	255
2016 Q4	$118M	Sell	1,484,241 -76,935	-5%	-$5.59M	0.1%	259
2016 Q3	$109M	Buy	1,561,176 +70,947	+5%	+$3.93M	0.09%	278
2016 Q2	$57.8M	Buy	1,490,229 +42,690	+3%	+$1.78M	0.05%	395
2016 Q1	$58.6M	Buy	1,447,539 +218,898	+18%	+$13.9M	0.05%	398
2015 Q4	$109M	Buy	1,228,641 +455,419	+59%	+$36M	0.09%	271
2015 Q3	$57.2M	Sell	773,222 -12,258	-2%	-$1.02M	0.05%	383
2015 Q2	$63.5M	Sell	785,480 -1,422	-0.2%	-$92.6K	0.05%	400
2015 Q1	$33M	Buy	+786,902	New	+$22.3M	0.03%	534

Other funds holding EGRX

PAI

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Janus Henderson Investors US's EGRX Position: Q1 2017 in Review

Janus Henderson Investors US reduced its Eagle Pharmaceuticals, Inc. (EGRX) stake by 2% in Q1 2017, selling an estimated $2.19M and leaving 1,454,778 shares worth $121M. The position accounts for 0.1% of the portfolio, ranked #255.

Janus Henderson Investors US first reported a position in EGRX in Q1 2015 and has held it in 9 quarters since. 147 funds tracked by Wall St. Rank hold EGRX as of Q1 2017.

Janus Henderson Investors US held 1,454,778 shares of Eagle Pharmaceuticals, Inc. worth $121M as of Q1 2017.
Janus Henderson Investors US sold 29,463 Eagle Pharmaceuticals, Inc. shares in Q1 2017, an estimated $2.19M.
Eagle Pharmaceuticals, Inc. made up 0.1% of Janus Henderson Investors US's portfolio in Q1 2017, its #255 holding.
Janus Henderson Investors US first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2015 and has held it in 9 quarters since.
147 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2017.

Based on Janus Henderson Investors US's 13F filing for Q1 2017, filed 16 May 2017.